TABLE I.
Summary of Baseline Patients’ Characteristics by Sex
| Variable | Category | Male (n = 1277) n (%) | Female (n = 1375) n (%) | P value* |
|---|---|---|---|---|
| Age categories (years) | ≤60 | 619 (48) | 636 (46) | 0.119 |
| 61–80 | 571 (45) | 617 (45) | ||
| >80 | 87 (7) | 122 (9) | ||
| Race/ethnicity | White | 1172 (92) | 1223 (89) | 0.102 |
| African American | 37 (3) | 55 (4) | ||
| Hispanic | 50 (4) | 69 (5) | ||
| Other | 18 (1) | 28 (2) | ||
| Grade | 1 or 2 | 906 (80) | 999 (80) | 0.994 |
| 3a | 232 (20) | 256 (20) | ||
| Missing | 139 | 120 | ||
| FLIPI risk category | Good (0–1) | 390 (38) | 360 (33) | 0.045 |
| Intermediate (2) | 313 (30) | 329 (30) | ||
| Poor (3–5) | 331 (32) | 396 (36) | ||
| Missing | 243 | 290 | ||
| Number of nodal sites | <5 | 809 (66) | 871 (66) | 0.958 |
| ≥5 | 417 (34) | 447 (34) | ||
| Missing | 51 | 57 | ||
| LDH level | Normal | 781 (79) | 814 (79) | 0.891 |
| >ULN | 207 (21) | 219 (21) | ||
| Missing | 289 | 342 | ||
| Hemoglobin (g/dL) | <12 | 180 (15) | 340 (27) | <0.0001 |
| ≥12 | 1014 (85) | 941 (73) | ||
| Missing | 83 | 94 | ||
| Stage | I or II | 421 (33) | 441 (32) | 0.681 |
| III or IV | 846 (67) | 917 (68) | ||
| Missing | 10 | 17 | ||
| ECOG PS | 0 | 605 (69) | 630 (66) | 0.133 |
| 1 | 232 (27) | 273 (29) | ||
| ≥2 | 34 (4) | 53 (6) | ||
| Missing | 406 | 419 | ||
| Extra-nodal sites | None | 590 (48) | 617 (46) | 0.548 |
| 1 | 403 (33) | 462 (35) | ||
| ≥2 | 239 (19) | 250 (19) | ||
| Missing | 45 | 46 | ||
| B-symptoms | Yes | 327 (26) | 344 (25) | 0.728 |
| No | 950 (74) | 1031 (75) | ||
| Bone marrow involvement | Yes | 367 (37) | 392 (39) | 0.464 |
| No | 617 (63) | 616 (61) | ||
| Missing | 293 | 367 | ||
| Geographical region | Midwest | 418 (33) | 418 (30) | 0.182 |
| Northeast | 214 (17) | 246 (18) | ||
| Southeast | 377 (30) | 443 (32) | ||
| Southwest | 108 (8) | 91 (7) | ||
| West | 160 (13) | 177 (13) | ||
| Centre type | Academic | 240 (19) | 276 (20) | 0.406 |
| Community | 1037 (81) | 1099 (80) |
FLIPI, Follicular Lymphoma International Prognostic Index; LDH, lactate dehydrogenase; ULN, upper limit of normal; ECOG PS, Eastern Cooperative Oncology Group performance score.
a
Pearson chi-square test.